NAYA Biosciences Inc NAYA

Healthcare Medical Devices

NAYA Biosciences, Inc. formerly INVO Bioscience, Inc. operates the fertility business, as well as its focus to the development of clinical-stage assets in oncology and autoimmune diseases. The Company’s initial pipeline includes two novel Flex-NK Bispecific Antibodies. NY-303: its GPC3-targeted FLEX-NK Bispecific Antibody for Hepatocellular Carcinoma (HCC). NY-338: its CD38-targeted FLEX-NK Bispecific Antibody for Multiple Myeloma (MM) & Autoimmune Diseases. Its lead GPC3-targeting FLEX-NK bispecific antibody is entering Phase I/II clinical trials and positioned as a monotherapy option to address the unmet needs of the of hepatocellular carcinoma (HCC) patients not responding to standard of care with checkpoint inhibitors. INVOcell is its novel, FDA-cleared and CE-marked intravaginal culture (IVC) device. It offers a viable alternative to vitro fertilization (IVF) that uses the female body for fertilization and incubation, keeping women at the center of the reproductive process.

NDAQ:NAYA - Post by User

NAYA Biosciences Inc

<< Previous

Bullboard Posts

Post by whytestockson Jan 13, 2025 5:30pm

30 Views

Post# 36402184

NAYA Biosciences Announces Pricing of $9.5 Million Public Of

NEWS: $NAYA NAYA Biosciences Announces Pricing of $9.5 Million Public Offering SARASOTA, Fla. and MIAMI, Jan. 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, today announced the pricing o...NAYA - NAYA Biosciences Announces Pricing of $9.5 Million Public Offering 

<< Previous

Bullboard Posts

Elon Musk sued by SEC over Twitter stock purchases